Polyomic clocks and longevity medicine

Visual identity, video production & graphics: Ines Kedjem

  • Portrait de Fabrice Denis, expert in prevention, health and well-being

    Prof. Fabrice Denis

Professor Fabrice Denis presents a modern view of aging, describing it as a profoundly heterogeneous process: at the same chronological age, biological trajectories can differ markedly from one individual to another.
He explains that measuring true biological age is a major challenge in anticipating disease risk and guiding personalized prevention strategies.
He details how biological clocks operate, based on molecular algorithms capable of predicting morbidity and mortality more accurately than chronological age.

He highlights epigenetic clocks, which rely on DNA methylation and reflect the impact of lifestyle and environmental factors.
He shows how their evolution, from first- to third-generation models, has strengthened their predictive value and clinical applicability.
According to him, the most recent models make it possible to measure the dynamic pace of aging and to ensure longitudinal monitoring of interventions.
Professor Denis also emphasizes the multisystemic nature of aging: organs do not age at the same rate, revealing distinct biological profiles.
He presents proteomic clocks that, through a simple blood test, estimate the biological age of 11 organs and refine risk assessment.
He advocates for an integrative approach combining standard biomarkers, functional tests, and molecular clocks to achieve a comprehensive and dynamic evaluation.
Finally, he outlines the promise of polyomic clocks, a cornerstone of a more precise, proactive, and personalized preventive medicine.

Preventive genetics & the medicine of tomorrow

Visual identity, video production & graphics: Ines Kedjem

  • Laure Raymond, expert in prevention, health and well-being

    Dr. Laure Raymond

Recent advances in genetics have profoundly transformed its role in healthcare, shifting from a deterministic vision to a predictive and actionable approach.
Dr. Raymond explains how genomic analysis has become a major driver of preventive medicine and healthcare system performance.
In 2025, neonatal genomic sequencing already enables the early detection of rare but treatable diseases, paving the way for broader screening.

In adults, around 3% of the population carries genetic variants associated with preventable or manageable conditions.
Large-scale international programs demonstrate clear clinical benefits, while France still needs to accelerate its efforts in this area.
Pharmacogenetics, the most mature field of preventive genetics, affects 99% of individuals and helps optimize treatment efficacy and safety.
It contributes to reducing adverse drug reactions, hospitalizations, and polypharmacy.
Health economic studies confirm short-term cost-effectiveness, with measurable savings within two years.
Preventive genetics is emerging as a strategic pillar of a more anticipatory, personalized, and efficient healthcare model.
The challenge now is organizational: fully integrating genetics at the heart of the healthcare system.